Erschienen in:
30.07.2015 | Original Article
Efficacy of lymph node dissection for each station based on esophageal tumor location
verfasst von:
Yuji Tachimori, Soji Ozawa, Hodaka Numasaki, Hisahiro Matsubara, Masayuki Shinoda, Yasushi Toh, Harushi Udagawa, Mitsuhiro Fujishiro, Tsuneo Oyama, Takashi Uno, The Registration Committee for Esophageal Cancer of the Japan Esophageal Society
Erschienen in:
Esophagus
|
Ausgabe 2/2016
Einloggen, um Zugang zu erhalten
Abstract
Background
The area of nodal dissection should be modified by the location of the primary tumor in an individual patient. The purpose of this study was to evaluate the efficacy of lymph node dissection based on station by the location of the primary tumor based on a multi-institutional nationwide registry of esophageal cancer.
Methods
The study group comprised 1295 patients who underwent R0 resection and three-field esophagectomy. The Efficacy Index (EI) was calculated by multiplying the incidence of metastases to a station and the 5-year survival rate of patients with metastases to that station, by tumor location.
Results
There were 550 patients without nodal metastases and 745 patients with them. In patients with upper tumors, the EIs of recurrent nerve nodes, cervical paraesophageal nodes and supraclavicular nodes were highest. In patients with middle tumors, the EIs of recurrent nerve nodes, cardiac nodes and lesser curvature nodes were highest, and the EIs of supraclavicular nodes and cervical paraesophageal nodes were not negligible. In patients with lower tumors, the EIs of cardiac nodes, lesser curvature nodes and left gastric artery nodes were highest, and the EIs of recurrent nerve nodes were also high.
Conclusion
The EIs of certain node stations were different by location of the primary tumor. Node stations for dissection should be modified by the location of the primary tumor. For upper and middle esophageal tumors, the three-field approach is recommended. Dissection of the upper mediastinum is recommended for patients with lower esophageal tumors.